Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg hikes target price on Balfour Beatty

(Sharecast News) - Analysts at Berenberg hiked their target price on Balfour Beatty from 660p to 710p on Tuesday as part of a wider look at the UK construction sector, citing a combination of strong year-to-date cash performance and peer multiples on the earnings-based business. Berenberg said it was clear that Balfour Beatty has undergone "quite a significant transformation" in recent years and it was now on "a much firmer footing".

The German bank said Balfour Beatty was now pricing and structuring contracts "far more sensibly" than it has done historically, which should result in "a more reliable earnings stream" in the coming years. It also said Balfour Beatty's balance sheet was "in good shape" and that the firm's valuation was underpinned by the investment portfolio.

Berenberg noted that aside from the key focus remaining on the ongoing delivery of steady cash-backed profit growth and the prospect for more shareholder returns, it also highlighted growth opportunities across the UK energy landscape, especially in transmission and generation, as well as growth and new opportunities in UK defence markets and a continued uptick in the US construction order book, with a focus on the Buildings business.

Berenberg, which has a 'buy' rating on the stock, added that Balfour trades on a 12.2x full-year 2026 price-to-earnings ratio, at 5.4x EBITDA and 7.1x EBIT.

When discussing the sector as a whole, Berenberg pointed to "an unhelpful economic backdrop" and "a mixed reporting season" for UK housebuilders, but noted that housing starts were now growing in 2025 - underpinning its view that "a slow and steady recovery" was underway.

In addition to the Balfour Beatty price target increase, Berenberg lowered its target price on Ibstock from 200p to 170p, raised Kier Group's target from 210p to 225p, and upped Volution from 700p to 720p. The analysts added that Taylor Wimpey remained their top pick.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.